[{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Congruence","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"GCase","graph1":"Neurology","graph2":"Discovery","graph3":"Congruence","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Congruence \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"2","companyTruncated":"Congruence \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

Find Clinical Drug Pipeline Developments & Deals by Congruence

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Study Phase : Discovery

                          Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                          Deal Size : $85.0 million

                          Deal Type : Funding

                          Details : The funding will be used to advance its GCase-targeting small molecules for GBA1 Parkinson's disease, including progressing novel development candidates through lead optimization towards the clinic.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 24, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                          Deal Size : $85.0 million

                          Deal Type : Funding

                          blank

                          02

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : The collaboration aims to discover novel small molecule drug candidates leveraging Congruence's proprietary drug discovery platform, Revenir, for the treatment of cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Under the agreement, Congruence will use its Revenir platform to develop small-molecule correctors targeting cancers. Ono has secured an exclusive global option for development and commercialization.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 12, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank